A diverse induction of apoptosis by trabectedin in MCF-7 (HER2-/ER+) and MDA-MB-453 (HER2+/ER-) breast cancer cells

Toxicology Letters

Volumn 221, Issue 2, 2013, Pages 128-136

  Atmaca, Harika ^a   Bozkurt, Emir ^a   Uzunoglu, Selim ^a   Uslu, Ruchan ^b   Karaca, Burcak ^b  

^a CELAL BAYAR UNIVERSITY   (Turkey)

^b EGE UNIVERSITY   (Turkey)

Author keywords

Apoptosis; Breast cancer; MCF 7; MDA MB 453; Reactive oxygen species; Trabectedin (Yondelis, ET 743)

Indexed keywords

CASPASE 3; CYTOCHROME C; DEATH RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROTEIN BAX; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; TRABECTEDIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; 1,3 DIOXOLANE DERIVATIVE; BAD PROTEIN, HUMAN; BAX PROTEIN, HUMAN; CASP3 PROTEIN, HUMAN; CASP7 PROTEIN, HUMAN; CASPASE 7; DIABLO PROTEIN, HUMAN; MITOCHONDRIAL PROTEIN; PROTEIN BAD; SIGNAL PEPTIDE; TETRAHYDROISOQUINOLINE DERIVATIVE; TNFRSF10A PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOTOXICITY; ECTEINASCIDIA TURBINATA; ENZYME METABOLISM; GENOTYPE; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; UROCHORDATA; BREAST TUMOR; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF 7 CELL LINE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-ASSOCIATED DEATH PROTEIN; BREAST NEOPLASMS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; CYTOCHROMES C; DIOXOLES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MCF-7 CELLS; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; REACTIVE OXYGEN SPECIES; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TETRAHYDROISOQUINOLINES;

EID: 84880370496     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2013.06.213     Document Type: Article

References (32)

1. Atmaca H., Gorumlu G., Karaca B., Degirmenci M., Tunali D., Cirak Y., Purcu D.U., Uzunoglu S., Karabulut B., Sanli U.A., Uslu R. Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. European Cytokine Network 2009, 20:121-130.
2. Bernard-Marty C., Cardoso F., Piccart M. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004, 9:617-632.
3. Carter N.J., Keam S.J. Trabectedin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs 2010, 70:355-376.
4. Chen L., Xu B., Liu L., Luo Y., Yin J., Zhou H., Chen W., Shen T., Han X., Huang S. Hydrogen peroxide inhibits mTOR signaling by activation of AMPKalpha leading to apoptosis of neuronal cells. Laboratory Investigation 2010, 90:762-773.
5. Chen L., Xu B., Liu L., Luo Y., Zhou H., Chen W., Shen T., Han X., Kontos C.D., Huang S. Cadmium induction of reactive oxygen species activates the mTOR pathway, leading to neuronal cell death. Free Radical Biology & Medicine 2011, 50:624-632.
6. Chen J.J., Shen H.C., Rivera Rosado L.A., Zhang Y., Di X., Zhang B. Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells. Oncotarget 2012, 3:833-842.
7. Cirak Y., Varol U., Atmaca H., Kisim A., Sezgin C., Karabulut B., Uzunoglu S., Uslu R., Karaca B. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A. BJU International 2012, 110:E1147-E1154.
8. Cuevas C., Francesch A. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem. Natural Product Reports 2009, 26:322-337.
9. David-Cordonnier M.H., Gajate C., Olmea O., Laine W., de la Iglesia-Vicente J., Perez C., Cuevas C., Otero G., Manzanares I., Bailly C., Mollinedo F. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chemistry & Biology 2005, 12:1201-1210.
10. Debatin K.M. Apoptosis pathways in cancer and cancer therapy. Cancer Immunology, Immunotherapy 2004, 53:153-159.
11. D'Incalci M., Galmarini C.M. A review of trabectedin (ET-743): a unique mechanism of action. Molecular Cancer Therapeutics 2010, 9:2157-2163.
12. Elmore S. Apoptosis: a review of programmed cell death. Toxicologic Pathology 2007, 35:495-516.
13. Hurley L.H., Zewail-Foote M. The antitumor agent ecteinascidin 743: characterization of its covalent DNA adducts and chemical stability. Advances in Experimental Medicine and Biology 2001, 500:289-299.
14. Gajate C., An F., Mollinedo F. Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells, Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. Journal of Biological Chemistry 2002, 277:41580-41589.
15. Gore L., Rivera E., Basche M., Moulder-Thompson S.L., Li J., Eppers S., Grolnic S., O'Bryant C., Cleere D., Elsayed Y.A., Eckhardt S.G. Phase I combination study of trabectedin and capecitabine in patients with advanced malignancies. Investigational New Drugs 2012, 30:1942-1949.
16. Grosso F., Jones R.L., Demetri G.D., Judson I.R., Blay J.Y., Le Cesne A., Sanfilippo R., Casieri P., Collini P., Dileo P., Spreafico C., Stacchiotti S., Tamborini E., Tercero J.C., Jimeno J., D'Incalci M., Gronchi A., Fletcher J.A., Pilotti S., Casali P.G. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncology 2007, 8:595-602.
17. Haupt S., Berger M., Goldberg Z., Haupt Y. Apoptosis - the p53 network. Journal of Cell Science 2003, 116:4077-4085.
18. Hendriks H.R., Fiebig H.H., Giavazzi R., Langdon S.P., Jimeno J.M., Faircloth G.T. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Annals of Oncology 1999, 10:1233-1240.
19. Keane M.M., Ettenberg S.A., Nau M.M., Russell E.K., Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Research 1999, 59:734-741.
20. Kisim A., Atmaca H., Cakar B., Karabulut B., Sezgin C., Uzunoglu S., Uslu R., Karaca B. Pretreatment with AT-101 enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of breast cancer cells by inducing death receptors 4 and 5 protein levels. Journal of Cancer Research and Clinical Oncology 2012, 138:1155-1163.
21. Krasner C.N., McMeekin D.S., Chan S., Braly P.S., Renshaw F.G., Kaye S., Provencher D.M., Campos S., Gore M.E. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. British Journal of Cancer 2007, 97:1618-1624.
22. Krasner C.N., Poveda A., Herzog T.J., Vermorken J.B., Kaye S.B., Nieto A., Claret P.L., Park Y.C., Parekh T., Monk B.J. Patient-reported outcomes in relapsed ovarian cancer: results from a randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone. Gynecologic Oncology 2012, 127:161-167.
23. ® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action. European Journal of Pharmacology 2011, 658:57-64.
24. Perou C.M., Jefrey S.S., van de Rijn M., Rees C.A., Eisen M.B., Ross D.T., Pergamenschikov A., Williams C.F., Zhu S.X., Lee J.C., Lashkari D., Shalon D., Brown P.O., Botstein D. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:9212-9217.
25. Perou C.M., Sørlie T., Eisen M.B., van de Rijn M., Jefrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., Fluge O., Pergamenschikov A., Williams C., Zhu S.X., Lønning P.E., Børresen-Dale A.L., Brown P.O., Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
26. Riccardi A., Meco D., Ubezio P., Mazzarella G., Marabese M., Faircloth G.T., Jimeno J., D'Incalci M., Riccardi R. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anticancer Drugs 2005, 16:811-815.
27. Riedl S.J., Salvesen G.S. The apoptosome: signalling platform of cell death. Nature Reviews Molecular Cell Biology 2007, 8:405-413.
28. Ryan D.P., Supko J.G., Eder J.P., Seiden M.V., Demetri G., Lynch T.J., Fischman A.J., Davis J., Jimeno J., Clark J.W. Phase I and pharmacokinetic study of Ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clinical Cancer Research 2001, 7:231-242.
29. Sanli U.A., Gorumlu G., Erten C., Gul M.K., Cengiz E., Kucukzeybek Y., Karaca B., Atmaca H., Uzunoglu S., Karabulut B., Uslu R. Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination. Cell Biology International 2009, 33:1165-1172.
30. Sessa C., De Braud F., Perotti A., Bauer J., Curigliano G., Noberasco C., Zanaboni F., Gianni L., Marsoni S., Jimeno J., D'Incalci M., Dall'ó E., Colombo N. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. Journal of Clinical Oncology 2005, 23:1867-1874.
31. Simon H.U., Haj-Yehia A., Levi-Schaffer F. Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000, 5:415-418.
32. Takano M., Ikeda Y., Kudoh K., Kita T., Sasaki N., Kikuchi Y. Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin. Journal of Obstetrics and Gynaecology Research 2012, (Epub ahead of print).